Upcoming Dividend • Jun 16
Upcoming dividend of CA$0.02 per share Eligible shareholders must have bought the stock before 23 June 2026. Payment date: 09 July 2026. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.5%). Ankündigung • May 11
CareRx Corporation announces Quarterly dividend, payable on July 09, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026. Ankündigung • Apr 28
CareRx Corporation to Report Q1, 2026 Results on May 06, 2026 CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026 Ankündigung • Mar 17
CareRx Corporation, Annual General Meeting, May 28, 2026 CareRx Corporation, Annual General Meeting, May 28, 2026. Ankündigung • Mar 10
CareRx Corporation announces Quarterly dividend, payable on April 09, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026. Ankündigung • Feb 25
CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026 CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026 Ankündigung • Dec 17
CareRx Corporation announces Quarterly dividend, payable on January 21, 2026 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025. Ankündigung • Oct 24
CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025 CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025 Ankündigung • Sep 17
CareRx Corporation announces Quarterly dividend, payable on October 15, 2025 CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025. Ankündigung • Jul 21
CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025 CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Ankündigung • May 01
CareRx Corporation to Report Q1, 2025 Results on May 07, 2025 CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025 Ankündigung • Mar 25
CareRx Corporation, Annual General Meeting, Jun 05, 2025 CareRx Corporation, Annual General Meeting, Jun 05, 2025. Ankündigung • Feb 26
CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025 CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025 Reported Earnings • Nov 10
Third quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.025 loss in 3Q 2023) Third quarter 2024 results: CA$0.006 loss per share (improved from CA$0.025 loss in 3Q 2023). Revenue: CA$92.8m (down 1.0% from 3Q 2023). Net loss: CA$360.0k (loss narrowed 75% from 3Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Ankündigung • Oct 31
CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024 CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024 Ankündigung • Sep 05
CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024 CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto. Reported Earnings • Aug 09
Second quarter 2024 earnings released: CA$0.023 loss per share (vs CA$0.033 profit in 2Q 2023) Second quarter 2024 results: CA$0.023 loss per share (down from CA$0.033 profit in 2Q 2023). Revenue: CA$92.0m (down 2.7% from 2Q 2023). Net loss: CA$1.38m (down 173% from profit in 2Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Ankündigung • Aug 02
CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024 CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024 Ankündigung • May 30
CareRx Corporation Announces Board Changes CareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation. Ankündigung • May 15
CareRx Corporation Announces CFO Transition CareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto. Reported Earnings • May 12
First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.039 loss in 1Q 2023) First quarter 2024 results: CA$0.009 loss per share (improved from CA$0.039 loss in 1Q 2023). Revenue: CA$89.7m (down 1.8% from 1Q 2023). Net loss: CA$517.0k (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Ankündigung • Mar 15
CareRx Corporation, Annual General Meeting, May 28, 2024 CareRx Corporation, Annual General Meeting, May 28, 2024. Ankündigung • Mar 08
CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023 CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023. Reported Earnings • Mar 08
Full year 2023 earnings released: CA$94.25 loss per share (vs CA$0.72 loss in FY 2022) Full year 2023 results: CA$94.25 loss per share. Revenue: CA$370.7m (down 2.9% from FY 2022). Net loss: CA$5.41m (loss narrowed 84% from FY 2022). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Ankündigung • Mar 01
CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024 CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024 New Risk • Nov 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€51.9m market cap, or US$57.0m). New Risk • Nov 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 25% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CA$9.1m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€62.6m market cap, or US$66.8m). Reported Earnings • Nov 10
Third quarter 2023 earnings released: CA$0.025 loss per share (vs CA$0.038 loss in 3Q 2022) Third quarter 2023 results: CA$0.025 loss per share (improved from CA$0.038 loss in 3Q 2022). Revenue: CA$93.8m (down 3.7% from 3Q 2022). Net loss: CA$1.44m (loss narrowed 19% from 3Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Ankündigung • Nov 02
CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023 CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023 Reported Earnings • Aug 11
Second quarter 2023 earnings released: EPS: CA$0.033 (vs CA$0.53 loss in 2Q 2022) Second quarter 2023 results: EPS: CA$0.033 (up from CA$0.53 loss in 2Q 2022). Revenue: CA$94.5m (down 2.5% from 2Q 2022). Net income: CA$1.88m (up CA$27.0m from 2Q 2022). Profit margin: 2.0% (up from net loss in 2Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Ankündigung • Aug 04
CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023 CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023 Board Change • Jun 08
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Jun 07
Carerx Corporation Announces Director Changes CareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election. Reported Earnings • May 10
First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022) First quarter 2023 results: CA$0.039 loss per share (improved from CA$0.059 loss in 1Q 2022). Revenue: CA$91.4m (down 1.9% from 1Q 2022). Net loss: CA$2.15m (loss narrowed 22% from 1Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 12
Forecast breakeven date pushed back to 2025 The 8 analysts covering CareRx previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 76% per year to 2024. The company is expected to make a profit of CA$1.96m in 2025. Average annual earnings growth of 86% is required to achieve expected profit on schedule. Reported Earnings • Mar 10
Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021) Full year 2022 results: CA$0.72 loss per share (further deteriorated from CA$0.65 loss in FY 2021). Revenue: CA$381.7m (up 45% from FY 2021). Net loss: CA$34.4m (loss widened 51% from FY 2021). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Ankündigung • Jan 19
CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,963,000
Price\Range: CAD 2.7
Discount Per Security: CAD 0.162 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Third quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.11 loss in 3Q 2021) Third quarter 2022 results: CA$0.038 loss per share (improved from CA$0.11 loss in 3Q 2021). Revenue: CA$97.4m (up 37% from 3Q 2021). Net loss: CA$1.78m (loss narrowed 55% from 3Q 2021). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 16
Second quarter 2022 earnings released: CA$0.53 loss per share (vs CA$0.28 loss in 2Q 2021) Second quarter 2022 results: CA$0.53 loss per share (down from CA$0.28 loss in 2Q 2021). Revenue: CA$96.9m (up 95% from 2Q 2021). Net loss: CA$25.1m (loss widened 196% from 2Q 2021). Over the next year, revenue is forecast to grow 7.5%, compared to a 7.7% growth forecast for the Consumer Retailing industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Jun 08
President recently sold €171k worth of stock On the 1st of June, David Murphy sold around 50k shares on-market at roughly €3.41 per share. This was the largest sale by an insider in the last 3 months. This was David's only on-market trade for the last 12 months. Breakeven Date Change • May 13
Forecast breakeven date pushed back to 2024 The 7 analysts covering CareRx previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 69% per year to 2023. The company is expected to make a profit of CA$2.40m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Board Change • May 03
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Maria Perrella was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Mar 19
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: CA$0.65 loss per share (up from CA$0.90 loss in FY 2020). Revenue: CA$262.6m (up 62% from FY 2020). Net loss: CA$22.7m (loss widened 25% from FY 2020). Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 46%, compared to a 7.0% growth forecast for the retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 11
Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$71.3m (up 56% from 3Q 2020). Net loss: CA$3.93m (loss narrowed 39% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 9 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$3.86m in 2022. Average annual earnings growth of 124% is required to achieve expected profit on schedule. Reported Earnings • Aug 11
Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$49.7m (up 25% from 2Q 2020). Net loss: CA$8.49m (loss narrowed 40% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Executive Departure • Jun 08
Director Lyle Oberg has left the company On the 5th of June, Lyle Oberg's tenure as Director ended after 1.5 years in the role. We don't have any record of a personal shareholding under Lyle's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years. Executive Departure • Jun 08
Director Peter Brown has left the company On the 5th of June, Peter Brown's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Peter's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 2.88 years. Breakeven Date Change • May 14
Forecast to breakeven in 2022 The 7 analysts covering CareRx expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2021. The company is expected to make a profit of CA$880.5k in 2022. Average annual earnings growth of 107% is required to achieve expected profit on schedule. Reported Earnings • May 14
First quarter 2021 earnings released: CA$0.21 loss per share (vs CA$0.37 profit in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: CA$44.9m (up 47% from 1Q 2020). Net loss: CA$5.87m (down 209% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year. Reported Earnings • Mar 12
Full year 2020 earnings released: CA$0.90 loss per share (vs CA$4.16 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$162.2m (up 30% from FY 2019). Net loss: CA$18.2m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 15% per year. Analyst Estimate Surprise Post Earnings • Mar 12
Revenue misses expectations Revenue missed analyst estimates by 3.1%. Over the next year, revenue is forecast to grow 29%, compared to a 1.6% growth forecast for the Consumer Retailing industry in Germany. Is New 90 Day High Low • Feb 13
New 90-day high: €3.16 The company is up 17% from its price of €2.70 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.48 per share. Is New 90 Day High Low • Jan 28
New 90-day high: €2.90 The company is up 14% from its price of €2.54 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.22 per share. Is New 90 Day High Low • Dec 15
New 90-day low: €2.22 The company is down 21% from its price of €2.80 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.13 per share. Ankündigung • Dec 03
CareRx Corporation Enters Multi-Year Pharmacy Services Agreement with an Ontario- Based Seniors Home Operator CareRx Corporation announced that it has entered into a multi-year pharmacy services agreement with an Ontario- based seniors home operator. The new contract, which commences in January 2021, will add approximately 1,100 new retirement and long-term care residents across 13 seniors housing communities, and is expected to be serviced through CareRx's existing infrastructure. Is New 90 Day High Low • Nov 27
New 90-day low: €2.44 The company is down 10.0% from its price of €2.72 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.14 per share. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue misses expectations Revenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 35%, compared to a 2.3% growth forecast for the Consumer Retailing industry in Germany. Reported Earnings • Nov 07
Third quarter 2020 earnings released: CA$0.28 loss per share The company reported a mediocre third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: CA$45.6m (up 45% from 3Q 2019). Net loss: CA$6.41m (loss widened 146% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 33% per year. Ankündigung • Nov 03
CareRx Corporation Announces Appointment of Puneet Khanna as Senior Vice President, Corporate Development CareRx Corporation announced that Puneet Khanna has joined the company as Senior Vice President, Corporate Development. Most recently, Mr. Khanna was Chief Executive Officer of MED e-care Healthcare Solutions Inc. Ankündigung • Oct 29
CareRx Corporation to Report Q3, 2020 Results on Nov 05, 2020 CareRx Corporation announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 05, 2020 Recent Insider Transactions • Oct 01
Insider recently bought €56k worth of stock On the 29th of September, Ryan Stempfle bought around 20k shares on-market at roughly €2.78 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €55k more in shares than they have sold in the last 12 months. Ankündigung • Aug 01
CareRx Corporation to Report Q2, 2020 Results on Aug 06, 2020 CareRx Corporation announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020 Ankündigung • Jul 30
Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others. Centric Health Corporation (TSX:CHH) entered into a share purchase agreement to acquire Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others for CAD 35.4 million on March 23, 2020. As per the terms, consideration will be payable in CAD 8 million of cash and issuance of 125 million common shares at closing. The consideration also includes CAD 8 million of deferred consideration, comprised of CAD 4 million of deferred consideration due 12 months following closing, and CAD 4 million of consideration payable under a vendor take-back note due 18 months following closing, each of which is to be paid in cash or in certain circumstances common shares and an earn-out consideration of up to CAD 5 million payable in cash if certain performance targets are achieved over the next two years. Centric Health entered into binding commitment letters with Crown Capital Partners Inc. and Yorkville Asset Management Inc. pursuant to which Crown Capital and Yorkville are expected to advance credit facilities up to CAD 42 million to Centric Health to refinance its existing senior and subordinated credit facilities and fund the cash closing price of the transaction, CAD 7 million will be used for acquisition. In the event the transaction does not close in certain circumstances, a termination fee of CAD 1 million may be payable by the Centric Health in cash or, in certain circumstances, common shares. Bruce Moody and the Remedy's Rx Specialty Pharmacy team will join to the Centric. As part of the Transaction, Moody will receive the right to nominate two Directors to the Centric's Board of Directors under certain circumstances and will be entitled to other customary governance rights, including pre-emptive rights and registration rights. RHI generated revenue of approximately CAD 60 million for the 12-month period ended September 30, 2019.
The transaction is subjected to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals and the consent of Centric Health shareholders. Under applicable Toronto Stock Exchange policies, the Centric Health is required to obtain shareholder approval for the transaction. As of April 23, 2020, Centric Health Corporation has obtained conditional approval of the transaction from the Toronto Stock Exchange and written consents from the requisite number of shareholders required to approve the transaction. The transaction is expected to close in the second quarter of 2020. As per filing on April 23, 2020, closing of the transaction will occur during the first or second week of May 2020. Origin Merchant Partners and BDO Canada LLP acted as the financial advisers to Centric Health, and NewPoint Capital Partners acted as the financial adviser to RHI.
Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others on May 7, 2020. Jeff May will join Centric Health as its new Chief Operating Officer. Bruce Moody, Founder and former principal shareholder and Chief Executive Officer of Remedy’s RX specialty pharmacy, has been appointed as Centric Health's Board of Directors today and Peter Brown as appointed as a Board observer and will be nominated for election as a Director at Centric Health’s 2020 Annual General Meeting. 
